Clinical microbiologyOccurrence of Clostridium difficile PCR-ribotype 027 and it's closely related PCR-ribotype 176 in hospitals in Poland in 2008–2010
Introduction
Clostridium difficile, a gram-positive, spore-forming, anaerobic bacterium, is an important causative agent of antibiotic-associated diarrhoea. The main virulence factors contributing to C. difficile infection (CDI) are two toxins: toxin A (TcdA), an enterotoxin, and toxin B (TcdB), a cytotoxin [1], [2]. Some strains can produce a third toxin, the so-called binary toxin (CDT) [3]. Since early 2003, increasing rates of CDI caused by binary toxin-positive C. difficile strains belonging to PCR ribotype 027 (type 027) were observed across North America and Europe [4], [5], [6]. These infections were characterised by a more severe course, higher mortality, increased frequency of relapse, and more complications [5], [7]. Outbreaks of CDI due to type 027 have been associated with fluoroquinolone use in particular, probably due to resistance against newer generation fluoroquinolones [8], [9], [10]. In Europe, C. difficile type 027 was first detected in 2005 in England and shortly thereafter, in the Netherlands. The first Polish isolate of C. difficile type 027 was found in 2005 and its related type 176 in 2008 [4], [11], [12]. We here report on the epidemiology of CDI caused by C. difficile types 027 and 176 in Poland during 2008–2010.
Section snippets
Materials and methods
An episode of CDI was defined for a patient with diarrhoea who tested positive for C. difficile toxins A/B and negative for other enteric pathogens, and/or showed evidence of toxin-producing C. difficile in the stool on the basis of toxigenic culture. We also defined CDI for any patient with pseudomembranous colitis diagnosed by colonoscopy. According to the European Centre for Disease Prevention and Control (ECDC)-proposed definitions [4], CDI is divided into healthcare-associated CDI,
Results
During the study period, a total of 2340 patients in three hospitals (H1, H2, and H3) were tested for CDI. Of these, 882 (37.7%) tested positive. The high positivity rate of 48% (2008) and 65% (2009) in hospital H1 can be explained by the local epidemiology of CDI in this hospital and the sensitivity of the routine testing protocol for stool samples. The CDI incidence in the three hospitals ranged from 3.2 to 3.9/10,000 patient-days (average, 3.6/1000 patient-days). Data of the incidence of CDI
Discussion
CDI outbreaks associated with types 027 and 176 have been documented in 3 hospitals in Poland in 2008–2010. Most likely, other hospitals in Poland also encountered outbreaks, since 2 patients had been transferred from another hospital. The CDI incidence in one hospital was higher (5.1 per 10,000 patient-days) than the CDI incidence reported in a pan-European study performed in 2008 (4.1 per 10,000 patient-days) [18]. The first ribotype 027 isolate of C. difficile from Poland originated in 2005
Competing interests
None declared.
Acknowledgements
This work was supported by National Centre of Science, Grant number DEC-2011/01/B/NZ7/02720.
We kindly thank Professor J. Wyzgał (Infant Jesus Teaching Hospital in Warsaw) in support and epidemiological data (hospital H1).
References (18)
- et al.
Binary toxin producing Clostridium difficile strains
Anaerobe
(2003) - et al.
Emergence of Clostridium difficile-associated disease in North America and Europe
Clin Microbiol Infect
(2006) - et al.
Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread
Lancet Infect Dis
(2010) - et al.
Diversity of moxifloxacin resistance during a nosocomial outbreak of a predominantly ribotype ARU 027 Clostridium difficile diarrhea
Anaerobe
(2009) - et al.
Clostridium difficile PCR ribotype 176 in the Czech Republic and Poland
Lancet
(2011) - et al.
ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey
Lancet
(2011) - et al.
Clostridium difficile infection: new developments in epidemiology and pathogenesis
Nat Rev Microbiol
(2009) - et al.
Both, toxin A and toxin B, are important in Clostridium difficile infection
Gut Microbes
(2011) - et al.
Update of Clostridium difficile infection due to PCR ribotype 027 in Europe
Euro Surveill
(2008)
Cited by (33)
Surveillance of antimicrobial susceptibilities reveals high proportions of multidrug resistance in toxigenic Clostridium difficile strains in different areas of Poland
2020, AnaerobeCitation Excerpt :The strains were highly resistant to multiple antibiotics (especially fluoroquinolones), which contributed to their survival and expansion in the hospital environment. Strains of NAP1/BI/RT027/toxinotype III posed a serious epidemiological problem in Poland in 2010–2014 [7–9]. Metronidazole and vancomycin are the first drugs of choice for CDI treatment [10].
The recognition and characterisation of Finnish Clostridium difficile isolates resembling PCR-ribotype 027
2018, Journal of Microbiology, Immunology and InfectionCitation Excerpt :The occurrence of RT176 has been reported from Czech Republic where it belongs to the prevailing ribotypes20 and from Poland where it persists with RT027.6,21 The clinical relevance of RT176 has been studied in both countries.21–23 Interestingly, four out of five Finnish RT176 isolates in this study were sent for molecular typing because of a severe course of CDI.
Clostridium difficile ribotype 176 - A predictor for high mortality and risk of nosocomial spread?
2016, AnaerobeCitation Excerpt :The emergence of PCR-ribotype 176 in the Czech Republic and Poland was reported in 2009 [23]. Whilst PCR-ribotype 176 occurs together with PCR-ribotype 027 in Poland [24], the occurrence of CDI caused by PCR-ribotype 027 in the Czech Republic is rare [5]. The spectrum of other PCR-ribotypes identified in the study corresponds with the spectrum of most frequent PCR-ribotypes from the European survey performed in 2008 [2].